• ASX childcare shares unlikely to receive support beyond June

    The federal government’s early childhood education and care relief package helped ASX childcare shares stay afloat at the height of the COVID-19 pandemic. However, as restrictions ease and Australians begin to go back to work, the free childcare scheme is unlikely to be extended beyond its expiry date of 28 June 2020.

    What is the free childcare scheme?

    In early April, the federal government pledged to support parents and childcare centres across the country by announcing that childcare would become free for parents who continue to work during the coronavirus pandemic.

    Additionally, the government announced it would provide financial support to childcare centres to ensure they continue to operate. As a result, the government has been paying childcare businesses 50% of their pre-COVID-19 revenue in the form of weekly ‘business continuity payments’.

    The scheme was no doubt a big relief to the many parents trying to balance both working at home and parenting at the same time. It has also been vital for many others such as nurses and doctors that have been required to leave their children in the care of others when they go to work.

    The announcement put a rocket under ASX childcare shares like G8 Education Ltd (ASX: GEM) and Think Childcare Ltd (ASX: TNK) at the time. However, following the initial boost, both shares remain relatively flat over the past month. G8 Education even tapped the market for capital in April to provide liquidity and strengthen its balance sheet.

    New report hails scheme as a success

    A report into the free childcare scheme has just been released by the Federal Education Department. The report was produced at the height of the pandemic and involved a survey of more than 7,000 child care providers.

    According to ABC News, the report concluded that the scheme fulfilled its aim of rescuing the sector and keeping services viable and open. It found that 86% of childcare services credited the scheme with helping them stay open, while 76% said the scheme helped them stay financially viable. The report also said that current childcare levels remain well below capacity at 63%.

    As quoted by ABC News, Education Minister Dan Tehan said:

    It is positive to see a report card like this but we cannot rest on our laurels because as demand continues to increase we’ve got to ensure that the sector will survive and flourish in a post pandemic world.

    Speaking to the Sydney Morning Herald, Mr Tehan further commented on the sustainability of the scheme:

    The success of the rescue package and the success we have had in flattening the curve means we do have to look at how long we want this temporary measure in place and how quickly do we need to change to meet the growing demand.

    What next?

    The current scheme is due to expire on 28 June 2020. While no final decision in regard to an extension has been made yet, Prime Minister Scott Morrison recently highlighted the temporary nature of the scheme. On Friday, Scott Morrison said that although the Education Minister is considering the program beyond its current expiry, it was “not a sustainable model for how the childcare sector should work”.

    As for ASX childcare shares, it will continue to be a tough road ahead as COVID-19 has had a significant adverse impact on occupancy levels across the sector. G8 Education and Think Childcare also carry a meaningful amount of debt to be serviced.

    Although G8 Education’s recent $301 million equity raising helped to substantially shore up its balance sheet, it is still in a net debt position of $65 million on an adjusted basis. The much smaller Think Childcare had around $30 million of net debt as of FY19 (ending 31 December 2019).

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading 40% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a <strong>significant discount</strong> to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    YES! SEND ME THE FREE REPORT!

    More reading

    Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post ASX childcare shares unlikely to receive support beyond June appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2WI5Ryp

  • Macquarie picks the best stocks to buy for the post COVID-19 rebound

    Winners Cup Trophy

    The S&P/ASX 200 Index (Index:^AXJO) is heading for its best session this month on growing optimism that the global economy is finally on the path to recovery.

    Markets may have passed peak COVID-19  pain and investors should be reassessing their ASX share portfolio to best position themselves for the post pandemic world.

    If you are looking for clues on the stocks you should and shouldn’t hold, Macquarie Group Ltd (ASX: MQG) may have some answers as its analysts looked at stock returns in the 1990 recession.

    Doesn’t repeat but rhymes

    That was the recession we had to have where the unemployment rate jumped to over 10%. Economists expect a similar outcome for the job market during this coronavirus-inspired recession.

    “We still think the market is in a range, as valuations limit upside. But without a second wave of Covid-19 and shutdowns, the worst of the contraction may have passed, and March 23 is the low,” said the broker.

    “This puts us in Late Contraction; that part of the recession where stocks often go up even when unemployment rises above 10% as it did months later in 1990-91.”

    Go overweight on resources

    One sector that the broker is overweight on during this part of the market cycle is resources. The BHP Group Ltd (ASX: BHP) share price outperformed during the recession two decades ago and Macquarie thinks this will happen again.

    Mind you, it’s not only BHP but also the other iron ore producers that Macquarie are tipping to be big winners this time round. This means you should add Rio Tinto Limited (ASX: RIO) and Fortescue Metals Group Limited (ASX: FMG) to the list as well.

    This is because the group is expected to generate strong free cash flows that can be used to pay dividends.

    Gold standard

    Gold miners also found a place in Macquarie’s model portfolio. The broker added Evolution Mining Ltd (ASX: EVN) and Saracen Mineral Holdings Limited (ASX: SAR) to its overweight list.

    Another sector to find favour is communications as media stocks outperformed in the last recession. Macquarie is backing NEWS CORP/IDR UNRESTR (ASX: NWS) over Nine Entertainment Co Holdings Ltd (ASX: NEC), and is keeping its bullish view on Telstra Corporation Ltd (ASX: TLS) for its defensive qualities.

    Bet on consumers

    Macquarie is also encouraging investors to increase their exposure to consumer discretionary stocks as cyclical stocks tend to outperform in a recovery. Stocks highlighted by the broker are Crown Resorts Ltd (ASX: CWN), Wesfarmers Ltd (ASX: WES) and Aristocrat Leisure Limited (ASX: ALL).

    Sectors to avoid

    On the flipside, Macquarie is recommending investors go underweight on financials, healthcare and technology.

    It is also suggesting investors reduce their exposure to Australian real estate investment trusts (AREITs).

    The experts at the Motley Fool have picked other winners to back in the rebound!

    5 “Bounce Back” Stocks To Tame The Bear Market (FREE REPORT)

    Master investor Scott Phillips has sifted through the wreckage and identified the 5 stocks he thinks could bounce back the hardest once the coronavirus is contained.

    Given how far some of them have fallen, the upside potential could be enormous.

    The report is called 5 Stocks For Building Wealth after 50, and you can grab a copy for FREE for a limited time only.

    But you will have to hurry — history has shown the market could bounce significantly higher before the virus is contained, meaning the cheap prices on offer today might not last for long.

    See the 5 stocks

    More reading

    Motley Fool contributor Brendon Lau owns shares of Aristocrat Leisure Ltd., BHP Billiton Limited, Macquarie Group Limited, Rio Tinto Ltd., and Telstra Limited. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited and Telstra Limited. The Motley Fool Australia owns shares of Wesfarmers Limited. The Motley Fool Australia has recommended Crown Resorts Limited and Nine Entertainment Co. Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Macquarie picks the best stocks to buy for the post COVID-19 rebound appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3e4IC7T

  • Moderna Prices $1.3B Equity Offering at $76/Share

    Moderna Prices $1.3B Equity Offering at $76/ShareModerna (MRNA) has now priced an underwritten public offering of 17,600,000 shares at a public offering price of $76 per share, before underwriting discounts and commissions.In addition, MRNA has granted the underwriters a 30-day option to purchase up to an additional 2,640,000 shares of common stock at the public offering price.Gross proceeds from the offering will be approximately $1.34 billion, says Moderna.The offering is expected to close on or about May 21, 2020, subject to customary closing conditions.Shares in Moderna pulled back 3% in Monday’s after-hours trading, following a 20% rally during the day after the biotech reported “positive” interim clinical data for its experimental coronavirus vaccine.“The interim Phase 1 data, while early, demonstrates that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection,” said Tal Zaks, Chief Medical Officer at Moderna.“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent Covid-19 disease and advance our ability to select a dose for pivotal trials.”Shares in Moderna have now exploded over 300% on a year-to-date basis- and as a result, the $76 average analyst price target now indicates 5% downside potential from current levels. (See Moderna stock analysis on TipRanks).However the stock still shows a bullish Strong Buy consensus from the Street, with six analysts reiterating their buy ratings on Monday. That includes Needham’s Alan Carr who ramped up his price target all the way from $58 to $94.“Based on these data, we believe the vaccine is likely to be found effective for prevention of infection in a Phase 3 trial” he explained. Carr believes a Phase 3 interim analysis by the end of 2020 appears feasible, which he says could be sufficient for FDA Emergency Use Authorization.“Given collaboration with Lonza, we expect Moderna to have meaningful supply by 4Q20. We have therefore added an mRNA-1273 revenue stream to our model and are raising our price target to $94” the analyst writes.Related News: Europe Could Conditionally Approve Gilead’s Remdesivir In Next Few Days Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data AstraZeneca Aiming For 30M UK Covid-19 Vaccine Doses By September More recent articles from Smarter Analyst: * Starbucks Back To Business In Japan Today * Uber Pops More Than 6% On Second Round Of Layoffs, Site Closures * Microsoft, FedEx Team Up To Make Package Delivery More Efficient * Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data

    from Yahoo Finance https://ift.tt/2ZkQrSz

Sorry, but nothing was found. Please try a search with different keywords.